Todos Medical and Orot+ Announce First Patient Enr
Post# of 30028
(Total Views: 504)
Posted On: 09/24/2019 3:38:57 PM
Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe
September 24, 2019 at 9:13 AM EDT
REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Orot+, the operational division of Orot-Luces (http://orot-luces.com), that executed a distribution agreement with Todos for the commercial distribution of Todos’ TM-B1and TM-B2 blood screening tests for breast cancer, today announced the enrollment of the first patient in the pre-commercial launch study of TM-B1 and TM-B2 in Europe. The pre-commercial launch study is expected to last approximately 6 months. Upon completion of the pre-commercial launch study, TM-B1 and TM-B2 are expected to be available for commercial sale in Romania by Orot. Orot is providing full funding for the pre-commercial launch study as well as the commercial launch in accordance with the terms of the exclusive distribution agreement.
“In accordance with the exclusive distribution agreement for both our TM-B1 and TM-B2 breast cancer screens in Romania and Austria executed in April 2019, Orot has commenced screening of patients as part of the agreed upon pre-sale preparation study required to support commercial launch in Romania. We are excited to achieve this critical milestone along our path to full commercialization in Europe,” said Dr. Herman Weiss, President & CEO of Todos Medical. “Our blood tests are designed to screen for the presence of breast cancer at early stages of disease, and we know that early diagnosis and treatment greatly improves patient outcomes.”
“The initiation of the pre-commercial study of Todos Medical’s TM-B1 and TM-B2 breast cancer blood screening tests will help create awareness among the medical community and local patient population of an affordable test that addresses the unmet need for improved breast cancer screening,” said Mr. Ron Streichman, CEO of Orot-Luces. “We have received encouraging feedback from medical practitioners and expect this to continue as they become aware of the significant potential for improved patients outcomes based upon the data generated in this patient population.”
http://investor.todosmedical.com/news-release...rolled-pre
Aloha
September 24, 2019 at 9:13 AM EDT
REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Orot+, the operational division of Orot-Luces (http://orot-luces.com), that executed a distribution agreement with Todos for the commercial distribution of Todos’ TM-B1and TM-B2 blood screening tests for breast cancer, today announced the enrollment of the first patient in the pre-commercial launch study of TM-B1 and TM-B2 in Europe. The pre-commercial launch study is expected to last approximately 6 months. Upon completion of the pre-commercial launch study, TM-B1 and TM-B2 are expected to be available for commercial sale in Romania by Orot. Orot is providing full funding for the pre-commercial launch study as well as the commercial launch in accordance with the terms of the exclusive distribution agreement.
“In accordance with the exclusive distribution agreement for both our TM-B1 and TM-B2 breast cancer screens in Romania and Austria executed in April 2019, Orot has commenced screening of patients as part of the agreed upon pre-sale preparation study required to support commercial launch in Romania. We are excited to achieve this critical milestone along our path to full commercialization in Europe,” said Dr. Herman Weiss, President & CEO of Todos Medical. “Our blood tests are designed to screen for the presence of breast cancer at early stages of disease, and we know that early diagnosis and treatment greatly improves patient outcomes.”
“The initiation of the pre-commercial study of Todos Medical’s TM-B1 and TM-B2 breast cancer blood screening tests will help create awareness among the medical community and local patient population of an affordable test that addresses the unmet need for improved breast cancer screening,” said Mr. Ron Streichman, CEO of Orot-Luces. “We have received encouraging feedback from medical practitioners and expect this to continue as they become aware of the significant potential for improved patients outcomes based upon the data generated in this patient population.”
http://investor.todosmedical.com/news-release...rolled-pre
Aloha
(2)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼